Physicians Area
Scientific rationale and available literature on Myo-inositol in the respiratory field.
Myo-inositol: key points overview
A focused selection of mechanisms described in the scientific literature and results reported in clinical studies.
Osmolyte and hydration
Myo-inositol acts as an osmolyte, meaning it is able to attract and retain water, contributing to the maintenance of adequate hydration of the mucus layer and the epithelial surface.
Mucociliary clearance
In a retrospective pilot study conducted in patients with bronchiectasis, aerosol administration of myo-inositol, twice daily for 15 days, resulted in a significant reduction in mucus solid content.
Pulmonary surfactant and neonatal respiratory medicine
Myo-inositol, mainly in the form of phosphatidylinositol, is a key component of pulmonary surfactant. Its role has been investigated in pre-clinical and clinical studies involving preterm infants with respiratory distress syndrome (RDS).
Myo-inositol in combination con N-acetil-L-cisteina (NAC)
Reduction of MIOX activity
Experimental studies suggest that NAC may modulate the expression and activity of MIOX (myo-inositol oxygenase), a key enzyme involved in myo-inositol catabolism, potentially contributing to increased bioavailability.
Enhanced mucociliary clearance
NAC acts as a mucolytic and mucoregulator, helping to reduce mucus viscosity and facilitate its elimination.
The osmolyte activity of myo-inositol promotes mucus hydration, further supporting mucociliary clearance.
Support of inflammation control
Myo-inositol and NAC may contribute to the modulation of acute and chronic inflammatory processes, acting on different molecular pathways such as PI3K/AKT and NF-κB, and protecting cells
from oxidative stress.
Myo-inositol in combination with Alpha-lactalbumin
Micronutrient absorption
Alpha-lactalbumin is a whey protein studied for its nutritional properties and its ability to influence the intestinal absorption mechanisms of specific micronutrients
In association with myo-inositol
Data available in the literature indicate that alpha-lactalbumin may enhance the intestinal absorption of myo-inositol, improving its systemic availability when administered orally.
Explore the literature
Selected bibliographic references on PubMed
Nebulized myo‑inositol increases mucus clearance in patients with bronchiectasis: a retrospective study
Eur Rev Med Pharmacol Sci. 2023 • PMID: 37522700
Myoinositol decreases N‑nitroso‑N‑methylurethane induced lung surfactant deficiency
Life Sci. 1982 • PMID: 6896899
Inositol supplementation in premature infants with respiratory distress syndrome
N Engl J Med. 1992 • PMID: 1560798
Respiratory distress syndrome and inositol supplementation in preterm infants
Early Hum Dev. 1985 • PMID: 3838720
Role of myoinositol in regulation of surfactant phospholipids in the newborn
Pediatr Res. 1985 • PMID: 3838720
Transcriptional and post-translational modulation of myo-inositol oxygenase by high glucose and related pathobiological stresses.
J Biol Chem. 2011 • PMID: 21652700
Nebulized myo-Inositol increases oxygen saturation and relieves symptoms in patients with airways diseases.
IJMDAT 2021 • DOI: 10.32113
Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro
Curr Drug Deliv. 2018 • PMID: 29745333
Safety note (food ingredient)
In the United States, inositol (myo-inositol) is included among substances affirmed as GRAS (Generally Recognized As Safe) as a food ingredient, under specific conditions of use.
Discover the Pneumoxytol® product line
For product information, please consult the dedicated product sheets.
Pneumoxytol® Ampoules for Aerosol
Pneumoxytol® Sachets